Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Investing Activities (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Cash from Investing Activities for 16 consecutive years, with -$3.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 11363.83% to -$3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2025, down 8236.82% year-over-year, with the annual reading at -$4.7 million for FY2025, 8236.82% down from the prior year.
  • Cash from Investing Activities hit -$3.1 million in Q4 2025 for Cumberland Pharmaceuticals, down from -$690837.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $680805.0 in Q3 2022 to a low of -$13.5 million in Q1 2022.
  • Historically, Cash from Investing Activities has averaged -$946535.0 across 5 years, with a median of -$95940.5 in 2023.
  • Biggest five-year swings in Cash from Investing Activities: soared 728.95% in 2022 and later plummeted 11363.83% in 2025.
  • Year by year, Cash from Investing Activities stood at -$26795.0 in 2021, then tumbled by 2291.39% to -$640772.0 in 2022, then skyrocketed by 140.68% to $260639.0 in 2023, then crashed by 110.29% to -$26809.0 in 2024, then tumbled by 11363.83% to -$3.1 million in 2025.
  • Business Quant data shows Cash from Investing Activities for CPIX at -$3.1 million in Q4 2025, -$690837.0 in Q3 2025, and $285864.0 in Q2 2025.